retatrutide peptide injection 🎙️ NEW EPISODE: Retatrutide—The Triple Agonist *Not licensed* Will this replace the current GLP-1 in the market., This triple receptor agonist (GIP/GLP-1/glucagon) is showing unprecedented results in How to Inject Retatrutide: Complete

Potential Benefits and Risks of Microdosing GLP-1 Microdosing GLP-1 is proposed to reduce dose-dependent gastrointestinal side effects such as nausea and vomiting, but lacks randomised controlled trial evidence for efficacy or safety

CrossRef SIRT3 ameliorates hepatic inflammation, oxidative stress, and fibrosis in HFD- or MCD diet-fed mice Huifang Lv, Wenyue Sun, Cuixia Tian, Chunyong Bian, Zhongting Lu, Xin Guo The Journal of Nutritional Biochemistry .2026

Investigating the same primary endpoint, TRANSCEND-T2D-2 (NCT06260722) will compare retatrutide to semaglutide in people with inadequately controlled T2D (treated with oral glucose-lowering treatments) over 26 months

Animal data on a GLP-1/GIP/glucagon triple agonist show strong effects on body weight reduction, and glucose- and lipid normalization in rodents